Method for preparing highly pure, highly effective natural killer cells and using such cells

LAP893AUndetermined Publication Date: 2026-05-08TS BIO CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
LAP893
Authority / Receiving Office
LA · LA
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-09-15
Filing Date
2021-09-14
Publication Date
2026-05-08

AI Technical Summary

Technical Problem

Current methods for producing Natural Killer (NK) cells are limited by low purity and efficiency, particularly in cancer patients, where the number and function of NK cells are reduced, making it difficult to secure sufficient cells for therapeutic use, and conventional culture technologies using cancer cells pose safety concerns.

Method used

A method involving the use of CD antibodies and cytokines, specifically interleukin-2, interleukin-12, and anti-CD16 antibodies, to enhance the proliferation and activity of NK cells without the need for support cells like cancer cells, including a two-step culture process to isolate and activate monocytes from peripheral blood.

Benefits of technology

This approach significantly increases the number and activity of NK cells, achieving high purity and efficiency, enabling effective cancer and infectious disease treatment by enhancing their cancer cell killing ability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0001_ABST
    Figure 00000000_0001_ABST
  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present invention relates to a method for preparing highly purified natural killer cells (NK cells) with high efficacy and, in particular, a composition for increasing the expansion and activation of NK cells and a method for preparing NK cells with improved proliferation and activation. The NK cell preparation technique according to the present invention enables highly purified NK cells to be obtained with high efficacy, and NK cells prepared by the method according to the present invention can be effectively used in the treatment of diseases such as cancer and autoimmune diseases on the basis of their high purity and excellent cancer killing ability.
Need to check novelty before this filing date? Find Prior Art

Description

Method for producing high-purity and high-efficiency natural killer cells and their uses

[0001] The present invention relates to a method for producing high-purity and high-efficiency natural killer cells (NK cells), and more specifically, to a composition for promoting the proliferation and activity of NK cells, and a method for producing NK cells with promoted proliferation and activity.

[0002]

[0003] Chemotherapy in cancer patients has the side effect of reducing the patient's immune cells and impairing immune function. Therefore, a treatment technique that transplants immune cells proliferated and activated ex vivo into the patient's body to reactivate the reduced number and function of these cells can be expected to have a synergistic effect when combined with existing chemotherapy. Furthermore, its effectiveness in eliminating residual and microscopic cancer after existing chemotherapy can prevent cancer recurrence.

[0004] Natural killer cells (NK cells), used in immunotherapy, are morphologically characterized by large granules in their cytoplasm and account for approximately 5-15% of lymphocytes in the blood. Like T cells and B cells, NK cells differentiate from common lymphoid progenitors and are cytotoxic lymphocytes that eliminate tumor cells and virus-infected cells. However, unlike conventional B cells, T cells, and dendritic cells (DC cells), NK cells can recognize cancer cells on their own without an activation process such as antigen presentation, and can directly kill cancer cells using enzymes such as granzymes and perforin. Defects in the differentiation and activity of these NK cells have been reported to be associated with various cancers, including breast cancer, melanoma, and lung cancer, and the superior killing ability of NK cells can be applied to new immunocytotherapy methods for the treatment of solid tumors and infectious diseases and for preventing rejection of bone marrow or organ transplants.

[0005] However, despite their potential as therapeutics for various diseases, NK cells exist in limited numbers in the body. Therefore, securing a large number of NK cells is crucial for their effective use in cell therapy. However, NK cells are not only rare in normal individuals, but their numbers, differentiation, and function are particularly impaired in cancer patients. This makes it difficult to secure sufficient numbers of cells for therapeutic use. Furthermore, mass proliferation and culture in vitro are not easy.

[0006] In this regard, various studies have been conducted on culture techniques to expand and activate NK cells to a practically useful level. For example, it has been reported that the existing NK cell culture technique using IL-2 or other cytokines and chemicals did not increase the number of NK cells dramatically compared to the initial one, and the results of effectively enhancing the proliferation of NK cells using culture techniques using feeder cells, such as irradiated cancer cells, MICA, 4-1BBL, and K562 cells transformed to express IL-15 have been reported (Tissue Antigens, 76(6): p467-475, 2010). However, all of these techniques have limitations in that they use cancer cells and are not suitable for ensuring important safety in clinical applications, such as the possibility of the cancer cells being mixed into cell therapy preparations.

[0007] Therefore, there is an urgent need for a method for obtaining high-purity and high-efficiency NK cells that can overcome these conventional problems while maintaining sufficient cancer cell killing ability and securing a large quantity of NK cells.

[0008]

[0009] The present inventors have conducted extensive research to establish an optimized NK cell manufacturing technology capable of overcoming the above-mentioned conventional problems and obtaining high-purity and high-efficiency NK cells, and as a result, have developed a method for manufacturing NK cells in which proliferation and activity are significantly enhanced by only adding CD antibodies and cytokines, including a process for distinguishing cultures for the purpose of activating and proliferating NK cells in the blood, without using support cells such as cancer cells, thereby completing the present invention.

[0010] Accordingly, the present invention aims to provide a composition for promoting the proliferation and activity of natural killer cells (NK cells).

[0011] In addition, another object of the present invention is to provide a method for producing natural killer cells (NK cells) with enhanced proliferation and activity.

[0012]

[0013] However, the technical problems to be solved by the present invention are not limited to the problems mentioned above, and other problems not mentioned will be clearly understood by those skilled in the art from the description below.

[0014]

[0015] In order to achieve the above-described purpose of the present invention, the present invention provides a composition for promoting the proliferation and activity of natural killer cells, comprising interleukin-2, interleukin-12, and anti-CD16 antibody as active ingredients.

[0016] In one embodiment of the present invention, the composition may further include at least one selected from the group consisting of interleukin-15, interleukin-18, anti-CD3 antibody, and anti-CD56 antibody.

[0017] In another embodiment of the present invention, the composition may further comprise autologous serum.

[0018] In addition, the present invention provides a method for producing natural killer cells, comprising the steps of: (a) isolating monocytes from peripheral blood of a mammal, including a human; (b) placing the monocytes and a culture medium in a culture flask coated with at least one selected from the group consisting of an anti-CD3 antibody, an anti-CD16 antibody, and an anti-CD56 antibody, and then performing primary culturing for 5 to 7 days; and (c) recovering the cultured cells and performing secondary culturing with the culture medium for 5 to 7 days, wherein the culture medium comprises at least one selected from the group consisting of interleukin-2, interleukin-12, interleukin-15, and interleukin-18, and autologous serum.

[0019] In one embodiment of the present invention, the autologous serum may be added at 5 to 15%.

[0020] In addition, the present invention provides natural killer cells produced by the above method.

[0021] In addition, the present invention provides a cell therapy agent for treating cancer, which comprises the natural killer cells as an active ingredient.

[0022] In addition, the present invention provides a cell therapy agent for treating infectious diseases, which comprises the natural killer cells as an active ingredient.

[0023] In addition, the present invention provides a method for preventing or treating cancer or an infectious disease, comprising a step of administering the natural killer cells to a subject in need thereof.

[0024] Additionally, the present invention provides the use of the natural killer cells for the manufacture of a drug for the prevention or treatment of cancer or infectious diseases.

[0025]

[0026] The NK cell manufacturing technology according to the present invention can significantly improve the proliferation and activity of NK cells, thereby obtaining NK cells with high purity and high efficiency, and can overcome the limitations of the conventional technology that uses cancer cells as support cells. Therefore, NK cells manufactured by the method according to the present invention can be usefully used in the treatment of various related diseases such as cancer, infectious diseases, and autoimmune diseases based on their high purity and excellent cancer cell killing ability.

[0027]

[0028] Figure 1 shows the results of FACS analysis performed to determine the proportion of NK cells in the culture obtained after the first activation culture and the second proliferation culture in the NK cell manufacturing process according to the present invention.

[0029] Figure 2 shows the results of analyzing the cancer cell killing rate of NK cells obtained after the first activation culture and second proliferation culture in the NK cell manufacturing process according to the present invention.

[0030] Figure 3 is a result showing a microscope image photograph of activated NK cells during the first activation culture and second proliferation culture processes in the NK cell manufacturing process according to the present invention.

[0031]

[0032] Hereinafter, the present invention will be described in detail.

[0033]

[0034] The present inventors have conducted extensive research to establish an optimized NK cell manufacturing method capable of overcoming the limitations of the conventional NK cell manufacturing technology and obtaining high-purity and high-efficiency NK cells, and as a result, have developed a method capable of manufacturing NK cells with enhanced proliferation and activity by only adding CD antibodies and cytokines, thereby completing the present invention.

[0035] Accordingly, the present invention provides a composition for promoting the proliferation and activity of natural killer cells, comprising interleukin-2, interleukin-12, and anti-CD16 antibody as active ingredients.

[0036] The term "cell proliferation" as used herein refers to an increase in the number of cells in a culture or differentiation of cells through a series of cell division stages. In the present invention, "natural killer cell (NK cell) proliferation" refers to an increase in the number of NK cells in a culture through cell division stages, or an increase in the number of cells through differentiation from immature blood cells into NK cells.

[0037] The term “enhancement of natural killer cell (NK cell) activity” used in the present invention includes an increase in the number of cells with cell killing ability that remove tumor cells or virus-infected cells in a culture, or an increase in the cell killing efficiency of individual NK cells, by transforming immature NK cells into mature NK cells or activating inactive NK cells.

[0038] In the present invention, the NK cells that serve as the raw material for the proliferation and activity enhancement may be purchased commercially or collected from a human or animal, and preferably may be supplied from a human in need of treatment with NK cells.

[0039] In addition, the NK cells may be isolated from any tissue source within the body, preferably from blood collected from the body, more preferably from whole blood, umbilical cord blood, bone marrow, or peripheral blood, and most preferably from peripheral blood.

[0040] In the present invention, the composition may further include at least one selected from the group consisting of interleukin-15, interleukin-18, anti-CD3 antibody, and anti-CD56 antibody.

[0041] The cytokine used in the present invention is a type of interleukin, and interleukin is a general term for proteinaceous bioactive substances produced by immune cells such as lymphocytes, monocytes, and macrophages. In the present invention, it is selected from the group consisting of interleukin-2 (IL-2), interleukin-12 (IL-12), interleukin-15 (IL-15), and interleukin-18 (IL-18), and IL-2 and IL-12 can be used in particular, and preferably, all of IL-2, IL-12, IL-15, and IL-18 can be used.

[0042] The anti-CD antibody used in the present invention is selected from the group consisting of an anti-CD16 antibody, an anti-CD3 antibody, and an anti-CD56 antibody. In particular, an anti-CD16 antibody can be used, and preferably, all of the anti-CD16 antibody, anti-CD3 antibody, and anti-CD56 antibody can be used.

[0043] The composition for promoting the proliferation and activity of NK cells of the present invention may additionally contain, in addition to the interleukin and anti-CD antibody, other essential components, carriers, or adjuvants, including autologous serum, for promoting the proliferation and activity of NK cells.

[0044] In another aspect of the present invention, the present invention provides a method for producing natural killer cells, comprising the steps of: (a) isolating monocytes from peripheral blood of a mammal, including a human; (b) placing the monocytes and a culture medium in a culture flask coated with at least one selected from the group consisting of an anti-CD3 antibody, an anti-CD16 antibody, and an anti-CD56 antibody, and performing primary culturing for 5 to 7 days; and (c) recovering the cultured cells and performing secondary culturing with the culture medium for 5 to 7 days, wherein the culture medium comprises at least one selected from the group consisting of interleukin-2, interleukin-12, interleukin-15, and interleukin-18, and autologous serum.

[0045] In the step (a) of the present invention, the peripheral blood mononuclear cells (PBMC) are isolated from the peripheral blood of a mammal, preferably a human, and mainly include immune cells such as B cells, T cells, and natural killer cells, and granulocytes such as basophils, eosinophils, and neutrophils. The PBMC can be prepared from peripheral blood collected from a living body by a conventional method. For example, in the present invention, the PBMC was separated from the peripheral blood using a gravity centrifugation method using Ficoll.

[0046] Additionally, the peripheral blood mononuclear cells may be obtained from the individual in need of treatment, i.e., autologous peripheral blood mononuclear cells. If the peripheral blood mononuclear cells are autologous, there is an advantage in that even if some T cells are present in the proliferated NK cell population, all cells are derived from the patient, eliminating the need to remove T cells.

[0047] The above step (b) of the present invention is a culture step for activating NK cells in peripheral blood mononuclear cells.

[0048] In the step (b) of the present invention, the method of coating the anti-CD antibody on a culture flask can be performed by placing a coating solution containing DPBS and the anti-CD3 antibody, anti-CD16 antibody, and anti-CD56 antibody mixed in the culture flask, dispersing the mixture evenly, and then allowing it to stand at 37°C for 2 to 6 hours, preferably 4 hours, or under refrigerated conditions for 16 to 24 hours, preferably 18 hours, and then washing to remove the coating solution.

[0049] After placing the monocytes and culture medium separated in step (a) into the above-mentioned coated culture flask, the culture can be carried out for 5 to 7 days, preferably 6 days, but the number of culture days can be appropriately set within the range of the above-mentioned range to obtain the desired NK cells by those skilled in the art. The number of inoculated cells is 1 x 10 based on a T75 flask. 6 It is desirable to inoculate cells greater than 10 cells.

[0050] In a specific embodiment of the present invention, as a result of the primary culture of step (b), an increase in the number of cells and a high cell viability of at least 87.6% were confirmed, and the ratio of NK cells increased from an average of 13.9% to 47.1%, and it was confirmed that when the activation culture period was extended by 1 day, the ratio of NK cells increased by an average of 15%.

[0051] The above step (c) of the present invention is a proliferation culture step for significantly increasing the number of NK cells.

[0052] The above step (c) of the present invention can be accomplished by recovering the cells cultured through the above step (b) and culturing them for 5 to 7 days using a culture medium of the same composition as in step (b), preferably culturing them for 6 days, but a person skilled in the art can appropriately set the number of culture days within the above range to obtain the desired NK cells.

[0053] In a specific embodiment of the present invention, as a result of the secondary culture in step (c), about 3 x 10 9 It was confirmed that NK cells accounted for a very high proportion of 94.42% among the canine cells and showed a high survival rate of 93.2%, and it was confirmed that they showed an average cancer cell killing rate of 70% against K562 cells, a thymoma cell line.

[0054] In the above steps (b) and (c), the culture conditions may be performed under typical cell culture conditions, i.e., at about 37°C in a CO2 incubator. In the present invention, a culture flask, more preferably a T75 flask, is used as the culture vessel, but a person skilled in the art may appropriately select and apply a commercially available culture dish, flask, plate, multi-well plate, or culture bag.

[0055] In the present invention, the basic medium added to the culture medium for producing NK cells may be an animal cell culture medium commonly used in the relevant technical field, such as RPMI1640 medium, CellGro medium, AIM-V medium, and XVIVO 20. In the present invention, RPMI1640 medium was used, but a person skilled in the art can appropriately select and apply the type of medium. In addition, the culture medium may additionally contain other components necessary for the proliferation and culture of NK cells in addition to the additives described above, if necessary.

[0056] In the present invention, the autologous serum additionally added to the culture medium may be added at 5 to 15%, preferably 7 to 12 v / v%, more preferably 9 to 11 v / v%, and most preferably 10 v / v%.

[0057] The present invention specifically demonstrated through examples that high-purity and high-efficiency NK cells can be obtained through the above NK cell production method compared to PBMC.

[0058] In another aspect of the present invention, the present invention provides natural killer cells produced by the above method.

[0059] In addition, the present invention provides a cell therapy agent for treating cancer, which comprises the natural killer cells as an active ingredient.

[0060] The above cancer may include all types of cancer, including solid cancer and blood cancer. Unlike blood cancer, solid cancer refers to cancer that forms a mass in an organ, and cancer that occurs in most organs falls under this category. There is no particular limitation on the types of cancer that can be treated using NK cells according to the present invention, and includes gastric cancer, liver cancer, lung cancer, colon cancer, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, cervical cancer, thyroid cancer, laryngeal cancer, acute myeloid leukemia, brain tumor, neuroblastoma, retinoblastoma, head and neck cancer, salivary gland cancer, lymphoma, etc.

[0061] In addition, the present invention provides a cell therapy agent for treating infectious diseases, which comprises the natural killer cells as an active ingredient.

[0062] The above infectious disease is a disease caused by infection with a virus or pathogen, and is a concept that includes all diseases that can be transmitted through respiratory tract, blood, skin contact, etc.

[0063] Non-limiting examples of such infectious diseases may include hepatitis B, hepatitis C, human papilloma virus (HPV) infection, cytomegalovirus infection, viral respiratory diseases, and influenza.

[0064] The term "treatment" may mean any action that improves or beneficially changes the symptoms of cancer or infectious disease in an individual by administering the above natural killer cells.

[0065] The above cell therapy agent may be provided as a cell therapy agent containing the active ingredient alone or including one or more pharmaceutically acceptable carriers, excipients or diluents.

[0066] Specifically, the carrier may be, for example, a colloidal suspension, a powder, a saline solution, a lipid, a liposome, microspheres, or nano-spherical particles. These may be complexed or associated with a carrier vehicle and may be transported in vivo using carrier systems known in the art, such as lipids, liposomes, microparticles, gold, nanoparticles, polymers, condensation agents, polysaccharides, polyamino acids, dendrimers, saponins, adsorption enhancing substances, or fatty acids.

[0067] When the above cell therapy agent is formulated, it can be prepared using diluents or excipients such as suspending agents, preservatives, and fillers that are commonly used. Formulations for parenteral administration can include sterile aqueous solutions, non-aqueous solvents, suspensions, and emulsions. Non-aqueous solvents and suspending agents can include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. In addition, for local administration, it can also include combinations with organic substances such as biopolymers, inorganic substances such as hydroxyapatite, specifically collagen matrices, polylactic acid polymers or copolymers, polyethylene glycol polymers or copolymers, and chemical derivatives thereof. When the above cell therapy agent is prepared in a formulation suitable for injection, the natural killer cells can be dissolved in a pharmaceutically acceptable carrier or frozen in a dissolved solution state. Pharmaceutically acceptable carriers and formulations suitable for the present invention, including those exemplified above, are described in detail in the literature [Remington's Pharmaceutical Sciences, 19th ed., 1995]. The cell therapy agent may be manufactured in unit dose form or may be manufactured by placing it in a multi-dose container by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method that can be easily performed by a person of ordinary skill in the art to which the present invention pertains.

[0068] The term "administration" refers to introducing a given substance into an individual through an appropriate method, and "individual" refers to any living organism, including humans, rats, mice, and livestock, that may harbor cancer or an infectious disease. A specific example may be a mammal, including humans.

[0069] The above cell therapy agent can be administered parenterally, and when administered parenterally, the injection method can be selected from external application to the skin or intraperitoneal injection, intrarectal injection, subcutaneous injection, intravenous injection, intramuscular injection, intraarterial injection, intramedullary injection, intracardiac injection, intrathecal injection, percutaneous injection, intranasal injection, intraenteric injection, local injection, sublingual injection, intrarectal injection, or intrathoracic injection.

[0070] The above cell therapy agent is administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" refers to an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment. The effective dosage level may be determined based on the type and severity of the patient's disease, the activity and sensitivity of the drug, the time of administration, the route of administration, and the excretion rate, the duration of treatment, concomitant medications, and other factors well known in the medical field. For example, based on an adult patient weighing 70 kg, about 1,000 to 10,000 cells / time, 1,000 to 100,000 cells / time, 1,000 to 1,000,000 cells / time, 1,000 to 10,000,000, 1,000 to 100,000,000 cells / time, 1,000 to 1,000,000,000 cells / time, 1,000 to 10,000,000,000 cells / time, or 1,000 to 100,000,000,000 cells / time, can be divided into one or several times a day at regular intervals, or can be administered multiple times at regular intervals.

[0071] In addition, the present invention provides a method for preventing or treating cancer or an infectious disease, comprising a step of administering the natural killer cells to a subject in need thereof.

[0072] The term "prevention" may mean any act of suppressing or delaying the onset of cancer or infectious disease in an individual by administering the above natural killer cells.

[0073] Additionally, the present invention provides the use of the natural killer cells for the manufacture of a drug for the prevention or treatment of cancer or infectious diseases.

[0074] Hereinafter, preferred examples are presented to aid in understanding the present invention. However, the following examples are provided solely to facilitate a better understanding of the present invention, and the scope of the present invention is not limited by the following examples.

[0075]

[0076] [Example]

[0077] Example 1. Method for producing high-purity and high-efficiency NK cells

[0078] The present inventors conducted experiments according to the following process to produce high-purity and high-efficiency NK cells.

[0079] 1) Collection of autologous blood

[0080] After collecting blood from the human body, it was placed in a Sodium Heparin Tube and a Plain Tube to prepare for blood separation.

[0081] 2) Culture flask coating

[0082] A coating solution was prepared by mixing 13 ml of DPBS and 1 ml of a mixture of CD3, CD16, and CD56 in a 50 ml tube. Next, 14 ml of the coating solution was placed in a T75 flask and evenly distributed over the entire surface. After incubation at 37°C for 4 hours or 18 hours in a refrigerator, the coating solution was removed and washed once with 10 ml of DPBS.

[0083] 3) Serum preparation

[0084] Blood from a plain tube was centrifuged at 2000 rpm at 4°C for 30 minutes. After centrifugation, the supernatant was collected, filtered using a 0.2 um membrane filter, and then stored in the refrigerator for use in culture.

[0085] 4) Isolation of immune cells

[0086] The blood in the heparin tube was transferred to the BSC and transferred to a 50ml tube to check the total amount, then mixed with an equal volume of DPBS. The same amount of Ficoll as the blood was transferred to a 50ml tube, and the mixture of DPBS and blood was added to the tube containing the Ficoll to prepare sufficient volume. Next, the prepared tube was centrifuged at 2000 rpm for 20 minutes at 4℃, and after centrifugation, the buffy coat layer was recovered and transferred to a new 50ml tube. DPBS twice the volume of the recovered buffy coat was added, and centrifugation was performed at 1200 rpm for 5 minutes at 4℃. After centrifugation, the supernatant was removed, the cells were well dispersed, and 20ml of twice the volume of DPBS was added and centrifuged at 1200 rpm for 5 minutes at 4℃. Afterwards, the supernatant was removed, the cells were released, the culture medium was added, the cells were resuspended, and the cell number was measured.

[0087] 5) Activation and culture of immune cells

[0088] IL-2, IL-12, IL-15, IL-18, and autologous serum were added to 50 ml of RPMI culture medium. The prepared culture medium was placed in a T75 flask, and more than 1,000,000 immune cells were seeded. The cells were activated and cultured for 6 days in a 37°C, 5% CO2 incubator.

[0089] 6) Proliferation and culture of immune cells

[0090] After 5 to 7 days of activation culture, all cultures were collected in a 50 ml tube and centrifuged at 1200 rpm, 5 min, 4 °C. The supernatant was then removed, the cells were released, resuspended by adding culture medium, and the cell number was measured. The cells were suspended in RPMI culture medium supplemented with IL-2, IL-12, IL-15, and IL-18 until the total volume was 200 ml, and seeded in 1000 ml polyvinyl culture medium. At this time, 4% autologous serum was added. The cells were cultured in a 37 °C, 5% CO2 incubator for 6 days.

[0091] 7) Add immune cell culture medium

[0092] After 3 to 5 days, when the culture medium turned yellow and colonies were formed, the cell number and viability were measured, and the culture medium was added to RPMI culture medium supplemented with IL-2, IL-12, IL-15, and IL-18 to make a total volume of 1000 ml.

[0093] 8) Recovery and replenishment of immune cells

[0094] After transferring the culture medium to four 250 ml tubes, the supernatant was discarded and centrifuged at 1200 rpm for 10 minutes at 4°C. After discarding the supernatant and thoroughly dissolving the cells, the cells were suspended in 100 ml of normal saline and the cell number and viability were measured.

[0095]

[0096] Example 2. Analysis of activation culture results - cell number / survival rate / NK cell ratio

[0097] The present inventors produced NK cells with enhanced proliferation and activity according to the process of Example 1. To this end, blood was first collected from four donors and the characteristics of the PBMCs in the blood were analyzed, with the results shown in Table 1 below.

[0098]

[0099] Blood volume, cell count, viability, NK ratio, N200515-01TS1881.43 x 10 892.517.0N200515-02TS1841.62 x 10 8 93.910.8N200612-01TS1129.4 x 10 7 89.31.6N200612-02TS1011.04 x 10 8 92.716.9average1461.04 x 10 8 92.113.9

[0100]

[0101] Next, the PBMC in the blood of each donor was activated and cultured according to the method described in Example 1 with an inoculation cell number of 2 x 10^7 / 50ml and an inoculation cell density of 4 x 10^5 / ml, and the cell number, survival rate, and proportion of NK cells after culture were analyzed.

[0102] First, as shown in Table 2 below, the cell count analysis results showed that an average of 10.0x10^7 cells were recovered on the 6th day of culture, and at least 8.23x10^7 cells could be obtained.

[0103]

[0104] 6 days N200515-01TS8.23E+07 N200515-02TS1.11E+08 N200612-01TS1.03E+08 N200612-02TS1.05E+08 Mean 1.00E+08 Standard deviation 1.25E+07

[0105]

[0106] Next, the cell viability was measured, and as shown in Table 3 below, the average cell viability on the 6th day was 88.85%, and the minimum viability was 87.6%.

[0107]

[0108] 6 days N200515-01TS89.9 N200515-02TS88.7 N200612-01TS89.2 N200612-02TS87.6 Average 88.85 Standard deviation 0.9

[0109]

[0110] Finally, analysis of the proportion of NK cells revealed that NK cells accounted for 47.1% on the 6th day of culture, and that the proportion of NK cells increased by an average of 15% when the activation culture period was extended by 1 day. More detailed results are shown in Table 4 below.

[0111]

[0112] 6 days N200515-01TS67.9 N200515-02TS68.1 N200612-01TS20.9 N200612-02TS31.5 Average 47.1 Standard deviation 24.5

[0113]

[0114] Example 3. Analysis of proliferation culture results - cell number / survival rate / NK cell ratio / cancer cell killing rate

[0115] After performing activation culture according to the method of Example 2 above, proliferation culture was performed for 6 days, and the cell number, cell viability, NK cell ratio, and cancer cell killing rate were measured.

[0116] First, as shown in Table 5 below, the cell count analysis results showed that approximately 3 billion cells were obtained on the 6th day of proliferation culture, and the results of 6 days of activation culture and 7 days of proliferation culture for each donor were as follows.

[0117]

[0118] 13th (6th + 7th) N200515-01TS3.66E+09 N200515-02TS2.34E+09 N200612-01TS2.62E+09 N200612-02TS3.16E+09 Average 2.95E+09 Standard deviation 5.86E+08

[0119]

[0120] Next, the results of the cell viability analysis are shown in Table 6 below, and the viability rate was 93.2% on the 6th day of culture.

[0121]

[0122] 13th (6th + 7th) N200515-01TS94.5 N200515-02TS95.2 N200612-01TS90.8 N200612-02TS92.4 Average 93.2 Standard deviation 2.0

[0123]

[0124] Next, the proportion of NK cells was measured using FACS. As a result, as shown in Figure 1, NK cells expressing CD56 accounted for 94.42% of the total, CD3 (T cells) for 2.10%, CD19 (B cells) for 1.84%, and CD14 (monocytes) for 0.79%.

[0125] Finally, we aimed to analyze the killing rate of the cultured NK cells against cancer cells. To this end, NK cells that had been activated and cultured for 6 days and expanded for 7 days were used. Cells from different donors (samples 1, 2, and 3) were treated with the K562 thymoma cell line. As shown in Figure 2, the results showed that NK cells exhibited an average cancer cell killing rate of 70%.

[0126] Additionally, Fig. 3 shows microscopic photographs showing activated NK cells during the culture process.

[0127] Through the above examples, it was confirmed that the NK cell manufacturing process according to the present invention dramatically increases the relative proportion of NK cells from 5 to 15% to 94.42% and increases the killing ability against cancer cells to about 70%, and thus it was found that the manufacturing of a high-purity and high-activity NK cell therapeutic agent is possible.

[0128]

[0129] The above description of the present invention is provided for illustrative purposes only. Those skilled in the art will readily appreciate that the present invention can be readily modified into other specific forms without altering the technical spirit or essential characteristics of the present invention. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive.

Claims

1. A composition for promoting the proliferation and activity of natural killer cells, comprising interleukin-2, interleukin-12, and anti-CD16 antibody as active ingredients.

2. In paragraph 1, A composition characterized in that the composition further comprises at least one selected from the group consisting of interleukin-15, interleukin-18, anti-CD3 antibody, and anti-CD56 antibody.

3. In paragraph 1, A composition characterized in that the composition further comprises autologous serum. 4.(a) A step of isolating monocytes from peripheral blood of a mammal, including a human; (b) a step of placing the monocytes and culture medium in a culture flask coated with at least one selected from the group consisting of anti-CD3 antibody, anti-CD16 antibody, and anti-CD56 antibody, and then performing primary culture for 5 to 7 days; and (c) A method for producing natural killer cells, comprising the step of recovering the cultured cells and performing secondary culture with the culture medium for 5 to 7 days, A manufacturing method, characterized in that the culture medium comprises at least one selected from the group consisting of interleukin-2, interleukin-12, interleukin-15, and interleukin-18, and autologous serum.

5. In paragraph 4, A manufacturing method characterized in that the autologous serum is added at 5 to 15%.

6. Natural killer cells manufactured by the method of Article 4.

7. A cell therapy agent for cancer treatment, comprising the natural killer cells of Article 6 as an active ingredient.

8. A cell therapy agent for treating infectious diseases, containing the natural killer cells of Article 6 as an active ingredient.